BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Tuesday reported a loss of $45.8 million in its third quarter.
The Boston-based company said it had a loss of 72 cents per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 91 cents per share.
The biotechnology firm posted revenue of $3.1 million in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VERV at https://www.zacks.com/ap/VERV
Advertisement